Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
102 patients who received third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan.
I · Intervention 중재 / 시술
third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND/OBJECTIVE] Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited later-line therapeutic options.
- 표본수 (n) 40
- p-value p = 0.033
- 95% CI 3.3-8.3
APA
Lan CC, Chang CY, et al. (2026). Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.. Journal of the Formosan Medical Association = Taiwan yi zhi. https://doi.org/10.1016/j.jfma.2026.01.057
MLA
Lan CC, et al.. "Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.." Journal of the Formosan Medical Association = Taiwan yi zhi, 2026.
PMID
41592988 ↗
Abstract 한글 요약
[BACKGROUND/OBJECTIVE] Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited later-line therapeutic options. This retrospective study aimed to evaluate the efficacy and safety of platinum-based chemotherapy as third-line treatment for metastatic PDAC.
[METHODS] We analyzed 102 patients who received third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan. All patients had previously received first-line gemcitabine-based therapy and second-line nanoliposomal irinotecan with 5-fluorouracil and leucovorin. Overall, one group (N = 40) received platinum-based regimens, whereas the other group (N = 62) received non-platinum-based treatments. Survival outcomes and treatment-related toxicities were compared between the groups.
[RESULTS] The median overall survival (OS) duration was 5.8 months (95 % CI, 3.3-8.3) for the platinum group and 4.3 months (95 % CI, 3.5-5.0) for the non-platinum group, without a statistically significant difference (HR, 0.74, 95 % CI: 0.46-1.18, p = 0.21). The median time-to-treatment failure was 2.4 months (95 % CI, 1.6-3.2) and 2.1 months (95 % CI, 1.3-2.9), respectively (HR, 0.85, 95 % CI: 0.57-1.28, p = 0.44). Subgroup analyses suggested that younger age and no history of pancreatectomy tended to associate with better OS following platinum-based treatment. However, the platinum group experienced a higher incidence aspartate aminotransferase elevation (13 % vs. 2 %, p = 0.033) and increased creatinine (13 % vs. 2 %, p = 0.033) levels than the non-platinum group.
[CONCLUSIONS] This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.
[METHODS] We analyzed 102 patients who received third-line systemic treatment for PDAC between 2018 and 2023 across five medical centers in Taiwan. All patients had previously received first-line gemcitabine-based therapy and second-line nanoliposomal irinotecan with 5-fluorouracil and leucovorin. Overall, one group (N = 40) received platinum-based regimens, whereas the other group (N = 62) received non-platinum-based treatments. Survival outcomes and treatment-related toxicities were compared between the groups.
[RESULTS] The median overall survival (OS) duration was 5.8 months (95 % CI, 3.3-8.3) for the platinum group and 4.3 months (95 % CI, 3.5-5.0) for the non-platinum group, without a statistically significant difference (HR, 0.74, 95 % CI: 0.46-1.18, p = 0.21). The median time-to-treatment failure was 2.4 months (95 % CI, 1.6-3.2) and 2.1 months (95 % CI, 1.3-2.9), respectively (HR, 0.85, 95 % CI: 0.57-1.28, p = 0.44). Subgroup analyses suggested that younger age and no history of pancreatectomy tended to associate with better OS following platinum-based treatment. However, the platinum group experienced a higher incidence aspartate aminotransferase elevation (13 % vs. 2 %, p = 0.033) and increased creatinine (13 % vs. 2 %, p = 0.033) levels than the non-platinum group.
[CONCLUSIONS] This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.